Psychiatr. pro Praxi, 2008; 9(5): 205-208

Individualized treatment in the light of current guidelines

prof. MUDr. Eva Češková CSc
Psychiatrická klinika LF MU a FN Brno

The paper deals with possibilities of individualized treatment within individual steps of actual Czech guidelines for treatment of depressive disorder. Giving the first choice includes all available antidepressants (AD), it is necessary to tailor the choice to the clinical picture and individual tolerability. At the level of the second step the strategies of AD change, dose escalation and augmentation are discussed in more details. The further strategies include combinations of antidepressants and other less common treatment options.

Keywords: Key words: guideline for treatment, depressive disorder, psychopharmacotherapy, antidepressants, individualized treatment.

Published: November 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Češková E. Individualized treatment in the light of current guidelines. Psychiatr. praxi. 2008;9(5):205-208.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Berney P. Dose-response relationship of recent antidepressants in the short-term treatment of depression. Dialogue Clin Neurosci 2006; 1: 249-262. Go to original source...
    2. Berman RM, Marcus RN, Swanink R et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007; 68: 843-853. Go to original source... Go to PubMed...
    3. Češková E. Kombinace antidepresiv. Remedia 2005; 15: 520-524.
    4. Češková E. Trazodon v neurologické praxi. Neurol. pro praxi 2006; 7: 114-116.
    5. Češková E. Duálně působící antidepresiva, Remedia 2006; 16: 594-597.
    6. Češková E. Jak správně zvolit antidepresivum. Psychiatr. pro Praxi 2007; 8: 229-231.
    7. Crossley NA, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry 2007; 68: 935-940. Go to original source... Go to PubMed...
    8. Dunner DL, Amsterdam JD, Shelton RC et al. Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study. J Clin Psychiatry 2007; 68: 1071-1077. Go to original source... Go to PubMed...
    9. Hannan N, Hamzah Z, Akinpeloye HO, Meagher D. Venlafaxine-mirtazapine combination in the treatment of persistent depressive illness. J Psychopharmacol 2007; 21:161-164. Go to original source... Go to PubMed...
    10. Hirschfeld RMA. Long-term side effects of SSRIs: sexual dysfunction and weight gain. J Clin Psychiatry 2003; 64 (suppl 18): 20-24.
    11. Kazaz RC, Apter JT, Cohen R et al. Combined treatment with sertraline and liothyronine in major depression. A randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 2007; 64: 679-688. Go to original source... Go to PubMed...
    12. Oberlander TF, Warburton W, Misri S et al. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using populationbased linked health data. Arch Gen Psychiatry 2006; 63: 898-906. Go to original source... Go to PubMed...
    13. Papakostas, GI. Limitations of contemporary antidepressants: tolerability. J. Clin. Psychiatry 2007; 68(suppl. 10): 11-17.
    14. Papakostas GI, Shelton RC, Smith J, Fava M. Augmentation of antidepressants with atypical medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry 2007; 68: 826-831. Go to original source... Go to PubMed...
    15. Papakostas GI, Fava M, Thase ME. Treatment of SSRI-resistant depression: a meta-analysis comparing within-versus across-class switches. Biol Psychiatry 2008; 63: 699-704. Go to original source... Go to PubMed...
    16. Posternak MA, Zimmermann M. Is there a delay in the antidepressant effect? J Clin Psychiatry 2005; 66: 148-158. Go to original source... Go to PubMed...
    17. Raboch J, Anders M, Praško J, Kellerová P (Eds.) Psychiatrie, Doporučené postupy psychiatrické péče II, Noctis Studio, 2006; 204 s.
    18. Raboch J, Anders M, Kryl M. Depresivní poruchy u dospělých. V: Raboch J, Anders M, Praško J, Kellerová P. (Eds.) Psychiatrie, Doporučené postupy psychiatrické péče II, Noctis Studio, 2006; 64-87.
    19. Ruhé HG, Huyser J, Swinkels JA, Schne AH. Dose escalation for insufficient response to standard-dose selective serotonin reuptake inhibitors in major depressive disorder. Systematic review. Br J Psychiatry 2006; 189: 309-316. Go to original source... Go to PubMed...
    20. Ruhé HG, Huyser J, Swinkels JA, Schene AH. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry 2006; 67: 1836-1855. Go to original source... Go to PubMed...
    21. Rush JA, Trivedi MH, Wisniewski SR et al. Bupropion-SR, sertraline or venlafaxine-XR after failure of SSRIs for depression. N Engl Med 2006; 354: 1231-1242. Go to original source... Go to PubMed...
    22. Shelton TC, Haman KL, Rapaport MH et al. A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorder. J Clin Psychiatry 2006; 67: 1674-1681. Go to original source... Go to PubMed...
    23. Souery D, Papakostas GI, Trivedi MH. Treatment-resistant depression. J Clin Psychiatry 2006; 67 (suppl 6): 16-22.
    24. Thase ME, Shelton RC, Khan A. Treatment with venlafaxine extended after SSRI nonresponse or intolerance. J Clin Psycopharmacol 2006; 26: 250-258. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.